Eli Lilly, the global pharmaceutical giant, has answered the prayers of millions of psoriasis and psoriatic arthritis patients in India with the launch of Copellor® (Ixekizumab). The drug, approved by the Drug Controller General of India (DCGI), is a humanized IgG4 monoclonal antibody that targets the IL-17A protein responsible for triggering and maintaining inflammation in psoriasis. Copellor® is now available in India in a single-dose prefilled autoinjector of 80mg/ml strength.
According to recent studies, psoriasis affects 125 million people worldwide, with a prevalence of 0.44-2.8% in India alone. Psoriatic arthritis, a type of inflammatory arthritis that affects some people with psoriasis, is also on the rise in India. Copellor®’s launch comes at a critical time when the number of psoriasis and psoriatic arthritis patients in India is increasing.
Vineet Gupta, Managing Director of Eli Lilly and Company – India & India Subcontinent, said: “The availability of a new treatment like Copellor® will now empower healthcare providers with another option for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, as well as treatment of adult patients with active psoriatic arthritis, a huge unmet need in the country.”
In conclusion, Eli Lilly’s Copellor® launch in India is a significant milestone that promises to improve the quality of life for millions of psoriasis and psoriatic arthritis sufferers. With Copellor®, patients now have an alternative treatment option to alleviate the impact of these debilitating conditions. Eli Lilly’s unwavering commitment to providing innovative treatments that improve patient outcomes is commendable, and their launch of Copellor® in India reaffirms their dedication to meeting the healthcare needs of people around the world.